Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* AFEYAN NOUBAR	2. Issuer Name and Ticker or Trading Symbol BG Medicine, Inc. [ BGMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O FLAGSHIP VENTURES, ONE MEMORIAL DRIVE, 7TH FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 12/3/2014
(Street) CAMBRIDGE, MA 02142 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/3/2014		X		464	A	$.04	92590	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		S ⁽²⁾		37	D	$.46 ⁽³⁾	92553	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		X		847	A	$.02	93400	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		S ⁽⁴⁾		31	D	$.46 ⁽³⁾	93369	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		X		1724	A	$0.02	95093	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		S ⁽⁵⁾		63	D	$0.46 ⁽³⁾	95030	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		X		1724	A	$.02	96754	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		S ⁽⁶⁾		63	D	$0.46 ⁽³⁾	96691	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		X		1724	A	$.02	98415	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/3/2014		S ⁽⁷⁾		63	D	$0.46 ⁽³⁾	98352	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock	12/4/2014		J ⁽⁸⁾		98352	D	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾
Common Stock								2434800	I	Held by NewcoGen Group LLC ⁽¹⁾
Common Stock								651560	I	Held by NewcoGen Equity Investors LLC ⁽¹⁾
Common Stock								92294	I	Held by NewcoGen-Long Reign Holding LLC ⁽¹⁾
Common Stock								215013	I	Held by AGTC Advisors Fund, L.P. ⁽¹⁾
Common Stock								2851447	I	Held by Applied Genomic Technology Capital Fund, L.P. ⁽¹⁾
Common Stock								1764286	I	Held by Flagship Ventures Fund 2007, L.P. ⁽⁹⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant to Purchase Common Stock (right to buy)	$.04	12/3/2014		X			464	⁽¹⁰⁾	7/10/2016	Common Stock	464	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾
Warrant to Purchase Common Stock (right to buy)	$.02	12/3/2014		X			847	⁽¹⁰⁾	3/28/2018	Common Stock	847	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾
Warrant to Purchase Common Stock (right to buy)	$.02	12/3/2014		X			1724	⁽¹⁰⁾	3/30/2020	Common Stock	1724	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾
Warrant to Purchase Common Stock (right to buy)	$.02	12/3/2014		X			1724	⁽¹⁰⁾	9/27/2020	Common Stock	1724	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾
Warrant to Purchase Common Stock (right to buy)	$.02	12/3/2014		X			1724	⁽¹⁰⁾	11/4/2020	Common Stock	1724	$0	0	I	Held by ST NewcoGen LLC ⁽¹⁾

Explanation of Responses:
( 1)	NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI"), NewcoGen-Long Reign Holding LLC ("NGLRH") and ST NewcoGen LLC ("STN", and together with NGG, NEI and NGLRH, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
( 2)	On December 3, 2014, STN exercised a warrant to purchase 464 shares of Common Stock for $0.04 per share. STN exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 37 of the warrant shares to pay the exercise price and issuing to STN the remaining 427 shares.
( 3)	The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
( 4)	On December 3, 2014, STN exercised a warrant to purchase 847 shares of Common Stock for $0.02 per share. STN exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 31 of the warrant shares to pay the exercise price and issuing to STN the remaining 816 shares.
( 5)	On December 3, 2014, STN exercised a warrant to purchase 1,724 shares of Common Stock for $0.02 per share. STN exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 63 of the warrant shares to pay the exercise price and issuing to STN the remaining 1,661 shares.
( 6)	On December 3, 2014, STN exercised a warrant to purchase 1,724 shares of Common Stock for $0.02 per share. STN exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 63 of the warrant shares to pay the exercise price and issuing to STN the remaining 1,661 shares.
( 7)	On December 3, 2014, STN exercised a warrant to purchase 1,724 shares of Common Stock for $0.02 per share. STN exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 63 of the warrant shares to pay the exercise price and issuing to STN the remaining 1,661 shares.
( 8)	In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report a pro-rata distribution by STN for no consideration to its members. The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction.
( 9)	Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
( 10)	This warrant is immediately exercisable.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
AFEYAN NOUBAR C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142	X	X
ST NewcoGen LLC C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X
KANIA EDWIN M JR C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X
Flagship Ventures Management, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X
NewcoGen Group, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA 02142		X

Signatures
/s/ Noubar Afeyan		12/5/2014
^** Signature of Reporting Person		Date
/s/ Noubar Afeyan, Authorized Signatory for ST NewcoGen LLC		12/5/2014
^** Signature of Reporting Person		Date
/s/ Edwin M. Kania, Jr.		12/5/2014
^** Signature of Reporting Person		Date
/s/ Noubar Afeyan, Authorized Signatory for Flagship Ventures Management, Inc.		12/5/2014
^** Signature of Reporting Person		Date
/s/ Noubar Afeyan, Authorized Signatory for NewcoGen Group, Inc.		12/5/2014
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.